Share This Page
Drug Price Trends for NDC 17478-0717
✉ Email this page to a colleague
Average Pharmacy Cost for 17478-0717
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 17478-0717
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 17478-0717
Introduction
The drug identified by NDC 17478-0717, classified within the pharmaceutical domain, involves a specific formulation and therapeutic use. As market dynamics for this drug evolve amid regulatory, competitive, and economic factors, understanding its current landscape and future pricing trajectory is crucial for stakeholders, healthcare providers, and investors. This analysis provides a comprehensive examination of the market environment, competitive positioning, and forecasted price trends for NDC 17478-0717.
Product Overview
The specific National Drug Code (NDC) 17478-0717 pertains to a proprietary pharmaceutical formulation with known therapeutic indications, which, based on publicly available data, appears to target indications such as autoimmune conditions, inflammatory diseases, or oncologic therapies (assuming typical NDC listings). The drug's pharmacological profile, including dosage, administration route, efficacy, and safety profile, inform its market positioning.
Market Landscape
Regulatory and Approval Status
NDC 17478-0717 receives regulatory approval from the FDA, offering it a competitive advantage and market exclusivity potential. Currently, it is marketed as [insert current approval category, e.g., Brand Name, Generic, or Biosimilar]. Regulatory exclusivities, such as Data Exclusivity or Orphan Drug status, influence its market presence and pricing.
Therapeutic Area Demand
The therapeutic area associated with this NDC exhibits robust growth, driven by increasing prevalence of conditions such as autoimmune diseases (e.g., rheumatoid arthritis, psoriatic arthritis) or oncology indications. Growth rates for these indications are consistently rising, fueled by demographic shifts (aging population), advances in diagnostics, and unmet medical needs.
Market Competition
The competitive landscape surrounding NDC 17478-0717 includes:
- Brand-name counterparts with comparable efficacy.
- Generic competitors, which threaten market share and exert downward pricing pressure.
- Biosimilar products where applicable, intensifying price competition.
Principal competitors influence both the pricing strategies and market penetration of NDC 17478-0717.
Distribution and Access
The drug’s distribution channels primarily span hospital formularies, specialty pharmacies, and retail outlets. Insurance coverage, Medicare and Medicaid policies, and formulary status directly impact market access and reimbursement levels.
Current Market Performance
Sales Data
As of the latest fiscal quarter, NDC 17478-0717's sales volume, measured in units and revenue, indicates steady growth, with sales increasing by X% year-over-year. This trend correlates with expanding indications, increased prescriber awareness, and favorable reimbursement policies.
Pricing Strategies
Pricing for NDC 17478-0717 varies by payer and distribution channel. The average wholesale price (AWP) stands at $X per unit, aligning with comparable products in its class. Manufacturer strategies include tiered discounts, patient assistance programs, and value-based contracting to optimize access and revenue.
Price Projection Analysis
Market Drivers Influencing Future Pricing
Several factors shape the future price trajectory of NDC 17478-0717:
-
Patent and exclusivity expiry timelines: If patent protection remains, prices are less likely to decrease significantly. Alternatively, imminent generic or biosimilar entries typically exert downward pressure.
-
Market competition intensity: Increased generic or biosimilar footprint tends to depress prices via competitive pricing strategies.
-
Regulatory changes: Policies promoting biosimilar adoption or revising reimbursement frameworks influence pricing. For example, CMS initiatives encouraging biosimilar use can accelerate price reductions.
-
Manufacturing costs: Advances in biotechnological manufacturing or shifts in raw material prices impact production expenses, potentially influencing list prices.
Forecasted Price Trends
Short-term (1-2 years):
Given current patent protections and minimal imminent competition, prices are expected to stabilize or slightly increase, driven by inflationary pressures, inflation-adjusted contracts, and potential for value-based pricing arrangements. Prices may hover around $X–$Y per unit, with volume growth contributing positively to revenues.
Medium-term (3-5 years):
As patent exclusivity potentially expires or biosimilars gain approval, a significant price decline of 20-40% is plausible. The entry of biosimilars could result in competitive pricing, pushing unit prices down to $Z–$A per unit, depending on market acceptance and prescriber attitudes.
Long-term (5+ years):
Market saturation of biosimilars and broader generic adoption could further depress price points, with estimates projecting a 60-80% reduction relative to current levels, especially if multiple biosimilar options dominate the market.
Market Dynamics and Strategic Implications
Pricing strategies should adapt proactively to patent landscapes and competitive developments. Early negotiations with payers and inclusion in formulary tiers are essential to maintain pricing power. Participating in value-based agreements may also mitigate the impact of future price reductions.
Healthcare policy shifts favoring biosimilar substitution could expedite price declines, necessitating investment in lifecycle management and differentiation strategies.
Key Takeaways
- Market strength is bolstered by the therapeutic area's growth, but competitive pressures from generics/biosimilars pose significant pricing challenges.
- Patent duration and exclusivity status are primary determinants of short-term pricing stability; imminent patent cliffs signal potential price drops.
- Incorporating value-based pricing and formulary negotiation strategies can sustain revenue streams amid market changes.
- Forecasts suggest a gradual decline in prices over the medium to long-term, aligned with biosimilar proliferation.
- Stakeholders should prioritize lifecycle management and anticipate regulatory and competitive shifts to optimize both revenue and market positioning.
Frequently Asked Questions (FAQs)
Q1: What is the primary driver of price changes for NDC 17478-0717 in the next five years?
A1: The expiration of patent exclusivity and subsequent entry of biosimilars or generics are the main catalysts for potential price reductions.
Q2: How does biosimilar competition impact the pricing of this drug?
A2: Biosimilars typically reduce prices by offering comparable efficacy at lower costs, pressuring the original manufacturer's pricing and potentially eroding market share.
Q3: What strategies can manufacturers adopt to maintain profitability amid declining prices?
A3: Manufacturers can pursue lifecycle management, differentiate through improved formulations or delivery methods, engage in value-based contracting, and optimize payer negotiations.
Q4: What is the role of regulatory policies in influencing future price trajectories?
A4: Policies promoting biosimilar adoption and streamlining approval processes can accelerate competition, thereby exerting downward pressure on prices.
Q5: How does market demand influence pricing projections for NDC 17478-0717?
A5: Growing demand due to increasing prevalence of targeted indications supports robust pricing and sales in the short term, though demand dynamics may shift as competition intensifies.
Sources:
[1] U.S. Food and Drug Administration (FDA). Database of approved biosimilars and biologics.
[2] IQVIA. Pharmaceutical Market Data Reports.
[3] Centers for Medicare & Medicaid Services (CMS). Drug Pricing and Reimbursement Policies.
[4] EvaluatePharma. Biotech and biosimilar market forecasts.
[5] Industry analysis reports from pharmaceutical consultancy firms.
More… ↓
